Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1999-02-16
2002-03-12
Marschel, Ardin H. (Department: 1631)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S069100
Reexamination Certificate
active
06355622
ABSTRACT:
Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic citation for these references may be found at the end of each series of experiments.
BACKGROUND OF THE INVENTION
Cancer is a complex multifactor and multistep process involving the coordinated expression and suppression of genes functioning as positive and negative regulators of oncogenesis (1-5). Direct cloning strategies, based on transfer of a dominant transforming or tumorigenic phenotype, have identified positive acting oncogenes (6-9). In contrast, the detection and cloning of genes that suppress the cancer phenotype have proven more difficult and elusive (10-15). A direct approach for isolating genes directly involved in regulating growth and differentiation involves subtraction hybridization between cDNA libraries constructed from actively growing cancer cells and cDNA libraries from cancer cells induced to lose proliferative capacity irreversibly and terminally differentiate (13,14). This experimental strategy has been applied to human melanoma cells, induced to terminally differentiate by treatment with recombinant human interferon &bgr; (IFN-&bgr;) and mezerein (MEZ), resulting in the cloning of novel melanoma differentiation-associated (mda) genes not previously described in DNA data bases (13,14). A direct role for specific mda genes in mediating growth and cell cycle control is apparent by the identification and cloning of mda-6 (13-16), which is identical to the ubiquitous inhibitor of cyclin-dependent kinases p21 (17). The importance of p21 in growth control is well documented and this gene has been independently isolated, as WAF-1, CIP-1, and SDI-1, by a number of laboratories using different approaches (18-20). These studies indicate that specific genes associated with proliferative control are induced and may contribute to the processes of growth arrest and terminal differentiation in human cancer cells.
The mda-7 gene was cloned from a differentiation inducer (IFN-&bgr; plus MEZ)-treated human melanoma (H0-1) subtracted library (13,14). The full-length mda-7 cDNA is 1718 nucleotides, and the major open reading frame encodes a novel protein of 206 aa with an M
r
of 23.8 kDa (21). Previous studies indicate that mda-7 is induced as a function of growth arrest and induction of terminal differentiation in human melanoma cells (14,21). mda-7 expression also inversely correlates with melanoma progression—i.e., actively growing normal human melanocytes express more mda-7 than metastatic human melanoma cells (21). Moreover, mda-7 is growth inhibitory toward human melanoma cells in transient transfection assays and in stable transformed cells containing a dexamethasone (DEX)-inducible mda-7 gene (21). These studies indicate that mda-7 may contribute to the physiology of human melanocytes and melanomas, and this gene has growth suppressive properties when overexpressed in human melanoma cells.
The mda-7 gene was also described in the International Patent Cooperation Treaty Application No. PCT/US94/12160, international filing date, Oct. 24, 1994 with Internation Publication No. WO95/11986, the content of which is incorporated into this application by reference.
This invention reports that mda-7 is a potent growth suppressing gene in cancer cells of diverse origin, including breast, central nervous system, cervix, colon, prostate and connective tissue. An inhibition in colony formation occurs in cancer cells containing defects in their p53 and/or retinoblastoma (RB) genes or lacking p53 and RB expression. In contrast, expression of mda-7 in normal human mammary epithelial cells, human skin fibroblasts and rat embryo fibroblasts induces quantitatively less growth suppression than in cancer cells. When stably expressed in human cervical carcinoma (HeLa) and prostate carcinoma (DU-145) cells, mda-7 has a negative effect on growth and transformation-related properties. The effects of mda-7 on HeLa cells are reversible following abrogation of the MDA-7 protein by infection with a genetically modified Ad5 vector expressing an antisense mda-7 gene. These observations indicate that mda-7 is a novel growth suppressing gene with a wide range of inhibitory actions in human cancers manifesting different genetic defects.
SUMMARY OF THE INVENTION
This invention provides a method for reversing the cancerous phenotype of a cancer cell by introducing a nucleic acid including a melanoma differentiation associated gene (mda-7) into the cell under conditions permitting the expression of the gene so as to thereby reverse the cancerous phenotype of the cell. This invention also provides a method for reversing the cancerous phenotype of cancer cell in a subject by introducing the above-described nucleic acid into the subject's cancerous cell.
This invention also provides a method for reversing the cancerous phenotype of a cancer cell by introducing the gene product of a melanoma differentiation associated gene (mda-7) into the cancer cell so as to thereby reverse the cancerous phenotype of the cell. This invention also provides a method for reversing the cancerous phenotype of a cancer cell in a subject by introducing the above-described gene product into the subject's cancerous cell.
This invention also provides a pharmaceutical composition having an amount of a nucleic acid including a melanoma differentiation associated gene (mda-7) effective to reverse the cancerous phenotype of a cancer cell and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition having an amount of the gene product of the above-described gene effective to reverse the cancerous phenotype of a cancer cell and a pharmaceutically acceptable carrier.
REFERENCES:
patent: 5480968 (1996-01-01), Kraus et al.
patent: 5643761 (1997-07-01), Fisher et al.
patent: 5710137 (1998-01-01), Fisher
patent: 9511986 (1995-05-01), None
Jiang, H, et al., (1996) “The melanoma differentiation associated gene mda-7 suppresses cancer cell growth”PNAS, 93:9160-9165.
Duguid, J.R., et al. (1988) “Isolation of cDNAs of scrapie-modulated RNAs by subtractive hybridization of a cDNA library”PNAS, 85:5738-5742.
Hara, E., et al. (1991) “Subtractive cDNA cloning using oligo (dT)30-latex and PCR: isolation of cDNA clones specific to undifferentiated human embryonal carcinoma cells”Nuc.Acds.Res., 19:7097-7104.
Hara, E., et al. (1993) “DNA-DNA Subtractive cDNA cloning using oligo (dT)30-Latex and PCR: Identification of Cellular Genes Which Are Overexpressed in Senescent Human Diploid fibrablasts”Anal.Bio., 214:58-64.
Herfort, M.R. and Garber, A.T. (1991) “Simple and Efficient Subtractive Hybridization Screening”BioTech., 11:598-603.
Jiang, H. And Fisher, P.B. (1993) “Use of a Sensitive and Efficient Subtraction Hybridization Protocol for the Identification of Genes Differentially Regulated During the Induction of Differentiation in Human Melanoma Cells”Mol.Cell.Differ., 1:285-299.
Jiang, H., et al. (1995) “Subtraction hybridization identifies a novel melanoma differentiation associated gene mda7, modulated during human melanoma differentiation, growth and progression”Oncogene, 11:2477-2486.
Lee, S.W., et al. (1991) “Positive selection of candidate tumor-suppressor genes by subtractive hybridization”PNAS, 88:2825-2829.
Maniatis, T., et al. (1982) “Strategies for cDNA cloning”Mol.Clon.: A Lab. Manual, Cold Spring Harbor Laboratory, 224-228.
Sive, H.L., et al. (1988) “A simple subtractive hybridization technique employing photoactivatable biotim and phenol extraction”Nuc.Acds.Res., 16:10937.
Travis, G., et al. (1988) “Phenol emulsion-enhanced DNA-driven subtractive cDNA cloning: Isolation of low-abundance monkey cortex-specific mRNAs”PNAS, 85:1696-1700.
Wieland, I., et al. (1990) “A method for difference cloning: Gene amplification following subtractive hybridization”PNAS, 87:2720-2724.
Marschel Ardin H.
The Trustees of Columbia University in the City of New York
LandOfFree
Use of a melanoma differentiation associated gene (mda-7)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of a melanoma differentiation associated gene (mda-7)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of a melanoma differentiation associated gene (mda-7)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2821906